August 11, 2026 at 12:00 PM ET

[Webinar] Rethinking Pediatric Sepsis-Associated AKI: What Clinicians Should Know About QUELIMMUNE®

This webinar introduces QUELIMMUNE®, an innovative therapy designed to address the underlying drivers of sepsis-associated AKI in pediatric patients on CRRT. QUELIMMUNE® the Selective Cytopheretic Device for Pediatrics (SCD-PED) is indicated for treatment of pediatric patients (weight ≥10kg and age ≤22 years) with acute kidney injury (AKI) due to sepsis or a septic condition on antibiotic therapy and requiring renal replacement therapy (RRT).

What you’ll learn

What can viewers anticipate learning?

The clinical burden and pathophysiology of pediatric sepsis-associated AKI
Key concepts behind the QUELIMMUNE® mechanism of action
Emerging evidence supporting its use and patient cases shared directly from Physician leaders in nephrology and critical care
Considerations for integrating QUELIMMUNE® into clinical practice
What institutions should know when evaluating new AKI therapies

Why attend

Why should you register/attend this?

Stay current on emerging therapies in pediatric AKI care
Gain practical insights for real-world clinical application
Explore whether QUELIMMUNE® may be appropriate for your institution
Access on-demand content after the live session

About QUELIMMUNE®

About QUELIMMUNE® and SeaStar Medical

QUELIMMUNE® the Selective Cytopheretic Device for Pediatrics (SCD-PED) is indicated for treatment of pediatric patients (weight ≥10kg and age ≤22 years) with acute kidney injury (AKI) due to sepsis or a septic condition on antibiotic therapy and requiring renal replacement therapy (RRT). The device is connected in-line to an existing hemodialysis delivery system’s extracorporeal continuous renal replacement therapy (CRRT) circuit.

QUELIMMUNE® was approved by FDA under a Humanitarian Device Exemption based on safety and probable benefit. The effectiveness of this device for this use has not been demonstrated. Adverse reactions observed in clinical studies include hypotension, hypothermia, tachycardia, hyperglycemia, and thrombocytopenia. Additional risks may include blood loss or extracorporeal circuit complications. QUELIMMUNE® must be used with citrate anticoagulation.

For complete risk information

Meet the experts

Leading clinicians sharing clinical experience and evidence

Dr. Stuart Goldstein MD, FAAP, FNKF

Cincinnati Children’s Hospital

Theresa Mottes APRN-NP, CPNP-AC, CDN

Lurie Children’s Hospital

Katie Plomaritas BSN, RN

Mott Children’s Hospital

Dr. Stephen Gorga MD, MSC, FAAP

University of Michigan

Dr. Kevin Chung, MD

Chief Medical Officer, SeaStar Medical

What is QUELIMMUNE®

Immunomodulation without immunosuppression

Chemistry

A Low-Calcium Environment

The therapy relies on standard Regional Citrate Anticoagulation (RCA) to maintain a strictly controlled, low-ionized calcium environment (≤0.39 mmol/L) within the circuit. This specific chemistry is required for the device’s immunomodulatory process to function.

Immune Cell Deactivation

Selective Cytopheresis in Action

Within this low-shear, low-calcium environment, the device’s synthetic hollow fiber membranes selectively target and bind highly activated, pro-inflammatory neutrophils and monocytes. This acts as a temporary “timeout” for the hyperactive white blood cells driving the cytokine storm, calming them down without permanently removing them from the body.

Integration

Seamless CRRT Integration

QUELIMMUNE® is not a standalone machine; it is designed as a simple adjunct therapy. It connects directly in-line to an existing continuous renal replacement therapy (CRRT) circuit (such as Prismaflex or PrisMax), creating a low-shear extracorporeal pathway for the patient’s blood.

Resolution

Restoring Systemic Homeostasis

Once deactivated, the targeted neutrophils undergo apoptosis, while the monocytes are reprogrammed into an anti-inflammatory, reparative phenotype. These calmed cells are then released back into systemic circulation, signaling the body to halt multi-organ damage and restore immune homeostasis—crucially achieving this without causing systemic immunosuppression.

Secure your spot today

August 2026. Live webinar. Expert faculty. Clinical insights you can implement immediately.

about quelimmune